Journal of Thrombosis and Thrombolysis

, Volume 42, Issue 2, pp 267–271 | Cite as

Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience

  • Kelsey Klute
  • Ersilia M. DeFilippis
  • Kelissa Shillingford
  • John Chapin
  • Maria T. DeSanchoEmail author


Splanchnic vein thrombosis (SVT) is an uncommon form of venous thrombosis. Management can be challenging due to underlying conditions, increased bleeding risk, and lack of evidence from clinical trials. We sought to characterize the presentation and management of patients with SVT at a large tertiary hospital. A total of 43 patients’ electronic medical records were reviewed. Median age at diagnosis was 43 (18–71). Sixteen patients had isolated portal vein thrombosis (37.2 %), and 16 (37.2 %) had thrombosis involving multiple splanchnic veins. Abdominal pain was the most common clinical presentation (67.4 %). Thrombophilia was present in 18 patients (41.9 %), nine had underlying liver disease (20.9 %) and seven had inflammatory bowel disease (16.3 %). Thirty-nine (90.7 %) patients were treated with anticoagulation, and 11(25.6 %) of these patients underwent interventional procedures. Thirty (69.8 %) patients remained on indefinite anticoagulation. Results of follow-up imaging at least 1 month after diagnosis were available for 29 patients; imaging showed chronic, stable thrombosis in 14 patients (48.3 %), resolution of thrombosis in 13 patients (44.8 %) and asymptomatic progression in two patients (6.9 %). Recurrent thrombosis occurred in four patients (9.3 %). Major bleeding occurred in eight patients who received anticoagulation (18.6 %), including fatal subdural hematoma in one patient. In this cohort of patients managed by hematologists and gastroenterologists, the majority of patients were treated with anticoagulation. Interventional procedures were higher than in previously reported series. Our study strongly supports the interdisciplinary management of splanchnic venous thrombosis.


Venous thrombosis Splanchnic circulation Registries Outcome 



We thank Dr. Stephen M. Pastores for his valuable suggestions to the manuscript.

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH (2006) Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 12:2115–2119CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ageno W, Riva N, Schulman S et al (2014) Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost 40:99–105PubMedGoogle Scholar
  3. 3.
    Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W (2012) Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 130(Suppl 1):S1–S3CrossRefPubMedGoogle Scholar
  4. 4.
    Amitrano L, Guardascione MA, Scaglione M et al (2012) Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. Eur J Gastroenterol Hepatol 24:1381–1385CrossRefPubMedGoogle Scholar
  5. 5.
    Yonal I, Pinarbasi B, Hindilerden F et al (2012) The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. J Thromb Thrombolysis 34:388–396CrossRefPubMedGoogle Scholar
  6. 6.
    Sekhar M, McVinnie K, Burroughs AK (2013) Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 162:730–747CrossRefPubMedGoogle Scholar
  7. 7.
    Hoekstra J, Leebeek FW, Plessier A et al (2009) Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 51:696–706CrossRefPubMedGoogle Scholar
  8. 8.
    Mutreja D, Kotru M, Sazawal S et al (2015) Hereditary and acquired thrombophilia in splanchnic vein thrombosis: a single-center experience. Clin Appl Thromb Hemost 21:521–526CrossRefPubMedGoogle Scholar
  9. 9.
    Bianchini M, De Pietri L, Villa E (2014) Coagulopathy in liver diseases: complication or therapy? Dig Dis 32:609–614CrossRefPubMedGoogle Scholar
  10. 10.
    Tait C, Baglin T, Watson H et al (2012) Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 159:28–38CrossRefPubMedGoogle Scholar
  11. 11.
    Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120:4921–4928CrossRefPubMedGoogle Scholar
  12. 12.
    Colaizzo D, Amitrano L, Guardascione MA et al (2013) Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res 132:e99–e104CrossRefPubMedGoogle Scholar
  13. 13.
    Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494SCrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kearon C, Akl EA, Ornellas J et al. (2016) Antithrombotic Therapy for VTE disease. Chest Guideline. Chest. doi: 10.1016/j.chest.2015.11.026
  15. 15.
    Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694CrossRefPubMedGoogle Scholar
  16. 16.
    Martinez M, Tandra A, Vuppalanchi R (2014) Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatol 60:425–426CrossRefGoogle Scholar
  17. 17.
    Lenz K, Dieplinger B, Buder R, Piringer P, Rauch M, Voglmayr M (2014) Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban. Z Gastroenterol 52:1175–1177CrossRefPubMedGoogle Scholar
  18. 18.
    Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424CrossRefPubMedGoogle Scholar
  19. 19.
    Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for Dabigatran Reversal. N Engl J Med 373:511–520CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Kelsey Klute
    • 1
  • Ersilia M. DeFilippis
    • 2
  • Kelissa Shillingford
    • 2
  • John Chapin
    • 1
  • Maria T. DeSancho
    • 1
    Email author
  1. 1.Division of Hematology and Medical OncologyWeill-Cornell Medical CollegeNew YorkUSA
  2. 2.Weill-Cornell Medical CollegeNew YorkUSA

Personalised recommendations